This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, Y. Articles by Young, A. Search for Related Content PubMed PubMed Citation Articles by Lee, Y. Articles by Young, A.

GTI-2040, an Antisense Agent Targeting the Small Subunit Component (R2) of Human Ribonucleotide Reductase, Shows Potent Antitumor Activity against a Variety of Tumors

Lorus Therapeutics Inc., Toronto, Ontario, M9W 4Z7 Canada

GTI-2040 is a 20-mer oligonucleotide that is complementary to a coding region in the mRNA of the R2 small subunit component of human ribonucleotide reductase. In vitro studies using a number of human tumor cell lines have demonstrated that GTI-2040 decreases mRNA and protein levels of R2 in a sequence- and target-specific manner. In vivo studies have shown that GTI-2040 significantly inhibits growth of human colon tumors (adenocarcinoma), pancreatic tumors (adenocarcinoma), liver tumors, lung tumors, breast tumors (adenocarcinoma), renal tumors, ovarian tumors (adenocarcinoma), melanoma, brain glioblastoma-astrocytoma, prostatic tumors, and cervical tumors in nude and/or severe combined immunodeficient mice. Antitumor effects were not observed with an oligonucleotide containing four mismatches to the R2 sequence or with a scrambled sequence containing the same base content but not complementary to R2. This suggests that an antisense mechanism is responsible for the in vivo observations. In addition to tumor growth assays, GTI-2040 was tested in a murine model of human lymphoma. Treatment of severe combined immunodeficient mice bearing Burkitt’s lymphoma with GTI-2040, but not control oligonucleotides, greatly extended the survival of mice, and survival extended well beyond the treatment period. Finally, GTI-2040 specifically inhibits metastasis of human melanoma cells to the lungs in nude mice. Taken together, the results of these studies indicate that GTI-2040 can act as a selective and specific anticancer agent against a broad range of human tumors.

This article has been cited by other articles:

				X. Wei, G. Dai, Z. Liu, H. Cheng, Z. Xie, R. Klisovic, G. Marcucci, and K. K. Chan Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase Drug Metab. Dispos., November 1, 2008; 36(11): 2227 - 2233. [Abstract] [Full Text] [PDF]

				H.-L. Devlin, P. C. Mack, R. A. Burich, P. H. Gumerlock, H.-J. Kung, M. Mudryj, and R. W. deVere White Impairment of the DNA Repair and Growth Arrest Pathways by p53R2 Silencing Enhances DNA Damage-Induced Apoptosis in a p53-Dependent Manner in Prostate Cancer Cells Mol. Cancer Res., May 1, 2008; 6(5): 808 - 818. [Abstract] [Full Text] [PDF]

				J. D. Heidel, J. Y.-C. Liu, Y. Yen, B. Zhou, B. S.E. Heale, J. J. Rossi, D. W. Bartlett, and M. E. Davis Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2207 - 2215. [Abstract] [Full Text] [PDF]

				D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]

				E. Koller, S. Propp, H. Zhang, C. Zhao, X. Xiao, M. Chang, S. A. Hirsch, P. J. Shepard, S. Koo, C. Murphy, et al. Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development Cancer Res., February 15, 2006; 66(4): 2059 - 2066. [Abstract] [Full Text] [PDF]

				A. A. Desai, R. L. Schilsky, A. Young, L. Janisch, W. M. Stadler, N. J. Vogelzang, S. Cadden, J. A. Wright, and M. J. Ratain A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors Ann. Onc., June 1, 2005; 16(6): 958 - 965. [Abstract] [Full Text] [PDF]

				Z. Dong, Y. Liu, and J.-T. Zhang Regulation of ribonucleotide reductase M2 expression by the upstream AUGs Nucleic Acids Res., May 11, 2005; 33(8): 2715 - 2725. [Abstract] [Full Text] [PDF]

				G. Dai, K. K. Chan, S. Liu, D. Hoyt, S. Whitman, M. Klisovic, T. Shen, M. A. Caligiuri, J. Byrd, M. Grever, et al. Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2005; 11(8): 2998 - 3008. [Abstract] [Full Text] [PDF]

				Z. P. Lin, M. F. Belcourt, J. G. Cory, and A. C. Sartorelli Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(-/-) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors J. Biol. Chem., June 25, 2004; 279(26): 27030 - 27038. [Abstract] [Full Text] [PDF]